{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-067794","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.437208+00:00","generated_at":"2026-06-18T05:40:32.672959+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Mirum reports immaterial SVB exposure (<1% of cash)","bullets":["Less than 1% of cash, equivalents, restricted cash and investments held at SVB.","SVB placed under FDIC receivership; company believes exposure is immaterial.","May experience delays in transferring funds due to banking system disruption.","No other financial impact disclosed as of March 10, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-067794","json":"https://secwatch.observer/filing/0001193125-23-067794.json","markdown":"https://secwatch.observer/filing/0001193125-23-067794.md","text":"https://secwatch.observer/filing/0001193125-23-067794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523067794/0001193125-23-067794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523067794/d475671d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:40:32.672959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}